Skip to main content
S&P 5007,659.44-1.09%DOW52,002.41-0.34%NASDAQ26,140.03-2.14%BTC$81,442.00-0.92%ETH$2,417.14-0.81%GOLD$4,186.70+0.40%OIL$99.04+2.63%
Smart Investors Daily
SID Premium
SN

NYSE · SNY

Sanofi

Healthcare · Drug Manufacturers - General

$40.61

Up+$0.32 (+0.79%)

Updated Oct 19, 2026, 7:17 AM

SID Score

6.2/10

Composite research score

Smart Money

54/100

Neutral

Market cap
119.04B
P/E ratio
11.2
Dividend yield
5.45%
52-week range
$39.07 – $52.68
Volume
4.63M
Avg. volume
2.95M

Price performance · SNY

SNY price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 16, 2026

SNY closed at $40.61 after 20 trading sessions, down 4.45% for the selected period.

Last close
$40.61
Period change
-4.45%
Period low
$39.12
Period high
$42.51
Daily close
View OHLC price history
SNY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 16, 2026$40.36$40.61$40.16$40.614.63M
Oct 15, 2026$40.64$40.87$40.17$40.295.05M
Oct 14, 2026$39.37$39.995$39.33$39.775.34M
Oct 13, 2026$40.12$40.12$39.07$39.123.99M
Oct 12, 2026$40.24$40.315$39.685$39.742.94M
Oct 9, 2026$40.17$40.305$39.92$40.072.1M
Oct 8, 2026$40.18$40.265$39.5848$40.233M
Oct 7, 2026$39.94$40.25$39.72$40.202.08M
Oct 6, 2026$40.05$40.05$39.235$39.563.05M
Oct 5, 2026$39.83$39.88$39.18$39.513.8M
Oct 2, 2026$39.58$40.07$39.50$39.924.34M
Oct 1, 2026$41.85$41.8759$40.635$40.676.68M
Sep 30, 2026$41.35$41.375$40.96$41.234.3M
Sep 29, 2026$40.58$40.80$40.40$40.743.04M
Sep 28, 2026$40.77$41.24$40.77$41.182.17M
Sep 25, 2026$40.89$41.12$40.655$41.112.22M
Sep 24, 2026$41.225$41.605$40.905$40.943.07M
Sep 23, 2026$41.85$41.96$41.405$41.663.84M
Sep 22, 2026$42.34$42.62$42.03$42.513.08M
Sep 21, 2026$42.64$42.775$42.47$42.502.48M

Latest SNY news

The latest Smart Investors Daily articles mentioning SNY.

Stock researchCompany · Overview

SNY research

Overview

Company profile and research snapshot.

Company profile

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$57.02
Implied upside
—
Analysts
14
SNY recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNNeutral—
Sep 21, 2026BERENBERGBuy—
Sep 8, 2026LEERINK PARTNERSOutperform—
Sep 4, 2026ODDO BHFBuy—
Aug 31, 2026INTESA SANPAOLO EQUITY RESEARCHBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 15, 2026

Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds

Regeneron Pharmaceuticals (REGN) shares have been in focus after the company reported quarterly revenue of US$4.29b, up 16.7% year on year. The results beat analyst expectations and have lifted the stock about 12.4% since the release. Regeneron Pharmaceuticals has been in a strong upswing, with a 7-day share price return of 7.68% and a 90-day share price return of 17.68%. The 1-year total shareholder return of 40.63% reflects momentum that has built over time as new drug data, expanded...

Yahoo · Oct 15, 2026

What Is Sanofi (ENXTPA:SAN) Really Gaining From Wider Canadian Access?

Sanofi (ENXTPA:SAN) reached a Letter of Intent with the pan-Canadian Pharmaceutical Alliance to broaden public coverage for Dupixent. The agreement targets expanded reimbursement for Dupixent across four additional indications within participating Canadian public drug plans. The pCPA Letter of Intent is intended to improve access for eligible patients while aligning pricing terms with Canadian payers. The Dupixent access deal with the pCPA deserves to be weighed against the rest of our...

Yahoo · Oct 15, 2026

Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data

Regeneron Pharmaceuticals has seen its share price move around in recent years, and fresh trial results plus a major immunology alliance are back in focus. With the stock closing at US$778.36 and investors watching new drug data closely, the open question is whether that price still lines up with what the business earns today. Over the past 5 years, Regeneron Pharmaceuticals has delivered a total return of 39.6%, which puts real pressure on the current earnings multiple to carry that...

Yahoo · Oct 15, 2026

Sanofi (ENXTPA:SAN) Stock Looks Reasonable After Its Antibody Deal

Sanofi has seen its share price under pressure over recent years, and a key issue for investors now is how well that current price lines up with what the business earns. The stock has declined 16.1% over the past 3 years, which raises a clear question about how the market is weighing Sanofi's earnings power against that weaker share performance. The expanded antibody alliance with Regeneron, including a US$1b upfront payment and potential milestones, may support expectations for future...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By